Survival and freedom from progression in autotransplant lymphoma patients is independent of stem cell source: Further follow-up from the original randomised study to assess engraftment
(2002) Leukemia and Lymphoma — Vol. 43, n° 3, p. 531-536 (2002)
Files
164495.pdf
Closed Access - Adobe PDF
- 223.34 KB
Details
- Authors
- Abstract
- Peripheral blood progenitor cells (PBPCs) have become the stem cell source of choice in autologous transplantation. In a prospective randomised trial, we previously demonstrated that autologous transplantation using filgrastim-mobilised PBPCs resulted in faster haematopoietic recovery with shorter hospitalisation and reduced platelet transfusions compared to bone marrow transplant (BMT). This study is a follow-up analysis evaluating the long-term clinical outcome. Seventy-two patients with advanced Hodgkin's disease or high-grade lymphoma were randomised to receive either filgrastim-mobilised PBPCs (n = 37) or bone marrow (n = 35) after BEAM chemotherapy. Fourteen patients withdrew from the study before commencing high-dose chemotherapy. Fourteen of the 58 patients who received treatment with chemotherapy and transplant have died, 6 (19%) in the ABMT arm and 8 (30%) in the PBPC transplant (PBPCT) arm. Twenty-five patients (81%) in the ABMT arm and 17 (63%) in the PBPCT arm, who received treatment, were in complete remission at the date of last follow-up. Progression-free survival and overall survival (OS) were similar for both arms (OS 81% at 46 months for ABMT versus 63% for PBPC; p = 0.38). Further prospective studies with larger number of patients need to be done to assess which source of stem cells may translate into a long-term clinical benefit for the patient.
- Affiliations
Citations
Kottaridis, P. D., Peggs, K., Schmitz, N., Dreger, P., Boogaerts, M. A., Ferrant, A., Demuynck, H. M., Zander, A., Link, H., Matcham, J., Linch, D. C., Borkett, K., & Goldstone, A. H. (2002). Survival and freedom from progression in autotransplant lymphoma patients is independent of stem cell source: Further follow-up from the original randomised study to assess engraftment. Leukemia and Lymphoma, 43(3), 531-536. https://doi.org/10.1080/10428190290012010 (Original work published 2002)